What is Dermata?
Dermata Therapeutics, Inc. operates as a late-stage medical dermatology enterprise dedicated to the identification, development, and commercialization of innovative pharmaceutical candidates. The company maintains a dual-focus strategy, addressing both chronic medical skin conditions and aesthetic applications. Its primary asset, XYNGARI, is currently undergoing rigorous Phase 3 clinical evaluation for the treatment of moderate-to-severe acne. Furthermore, the company has successfully completed Phase 1b proof-of-concept trials for mild-to-moderate psoriasis, demonstrating a robust pipeline capable of addressing significant unmet needs in the dermatology sector.
How much funding has Dermata raised?
Dermata has raised a total of $9.4M across 1 funding round:
Other Financing Round
$6.2M
Other Financing Round (2025): $6.2M, investors not publicly disclosed
Key Investors in Dermata
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Dermata?
Following this major enterprise-level funding, Dermata Therapeutics is expected to prioritize the advancement of its clinical pipeline, specifically focusing on the regulatory milestones for XYNGARI. The strategic allocation of this capital will likely support the completion of ongoing Phase 3 studies and the subsequent preparation for commercialization pathways. By leveraging this financial backing, the company aims to solidify its market position as a leader in medical dermatology, potentially expanding its therapeutic footprint into broader aesthetic and dermatological markets as it transitions from a clinical-stage developer to a commercial-ready pharmaceutical entity.
See full Dermata company page
